Article
New use permitted: FDA approves latanoprost as first-line IOP reducer
Peapack, NJ-Pharmacia Ophthalmology will begin making its latanoprost ophthalmic solution(Xalatan) available for initial treatment of elevated eye pressure associated with open-angle glaucoma or ocular hypertension.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
